GlassScriptPhysician profile
Dahlia T Carr
NPI 1356368930
$14,240.15
in general payments reported to CMS, 2019-2025
34 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,420 · 2020: $1,044 · 2021: $1,859 · 2022: $2,063 · 2023: $1,924 · 2024: $2,249 · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,848 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,847.79 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,100.22 | 2019-2025 | Evenity, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $1,933.76 | 2019-2025 | Benlysta |
| Abbvie INC. | $1,743.65 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $1,453.49 | 2019-2025 | Tremfya |
| Radius Health, INC. | $655.59 | 2019-2025 | Tymlos |
| Pfizer INC. | $497.79 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $484.36 | 2020-2025 | Acthar |
| Lilly USA, LLC | $478.41 | 2019-2025 | Taltz, Zepbound |
| Ucb, INC. | $461.29 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $419.21 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.60 | 2020-2025 | Ofev, Cyltezo |
| Depuy Synthes Sales INC. | $209.34 | 2019-2025 | Monovisc, Orthovisc |
| Sobi, INC | $180.52 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $171.63 | 2021-2024 | Saphnelo |
| Horizon Therapeutics Plc | $165.01 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $164.38 | 2019 | |
| Celgene Corporation | $140.41 | 2019 | |
| Genzyme Corporation | $127.10 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $68.06 | 2022 | |
| Pacira Therapeutics, INC. | $63.70 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $61.35 | 2022-2023 | Arcalyst |
| Fresenius Kabi USA, LLC | $52.67 | 2023 | Idacio |
| Genentech USA, INC. | $49.14 | 2024-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $47.99 | 2019 | |
| Fidia Pharma USA INC. | $36.09 | 2025 | Triluron, Hymovis |
| Kiniksa Pharmaceuticals International, Plc | $32.34 | 2024 | Arcalyst |
| Mindera Corp | $27.72 | 2025 | |
| Organon LLC | $27.68 | 2024 | |
| Bioventus LLC | $24.04 | 2019 | |
| Sandoz INC. | $23.78 | 2025 | Jubbonti |
| Medexus Pharma, INC. | $22.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.12 | 2021 | |
| Antares Pharma, INC. | $17.74 | 2019 | |
| Aurinia Pharma U.S., INC. | $13.12 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dahlia Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.